AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6617205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combination of 1-norgestrel 150 micrograms and ethinyl estradiol 30 micrograms
Number of subjects: 21
Study 6617205 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated IUD (control group)
Number of subjects: 21
Study 31919403 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) models
Number of subjects: 0
Study 30719589 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 0
Study 30719589 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study 29336128 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-enriched gelfoam
Number of subjects: 24
Study 29336128 — intervention group
Group type: COMPARATOR
Intervention: Conventional gelfoam
Number of subjects: 24
Study 26674292 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment (procedures and drinking cure)
Number of subjects: 96
Study 24703722 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab arm A (4-week loading dose of 0.4 mg/kg/wk followed by 1.6 mg/kg every 2 weeks)
Number of subjects: 225
Study 24703722 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab arm B (1.6 mg/kg every 2 weeks)
Number of subjects: 225
Study 24703722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 24703722 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab arm A
Number of subjects: 225
Study 24703722 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab arm B
Number of subjects: 225
Study 24703722 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (A, B, placebo)
Number of subjects: 225
Study 22189537 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) vaccination immediately at first health center contact
Number of subjects: 105
Study 19775046 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg (Group IA)
Number of subjects: 20
Study 19775046 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg (Group IB)
Number of subjects: 20
Study 19775046 — intervention group
Group type: COMPARATOR
Intervention: Propofol (Group IIA)
Number of subjects: 20
Study 19775046 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (Group IIB)
Number of subjects: 20
Study 17523339 — intervention group
Group type: EXPERIMENTAL
Intervention: D4 gastrectomy
Number of subjects: 270
Study 17523339 — intervention group
Group type: COMPARATOR
Intervention: D2 gastrectomy
Number of subjects: 270
Study 15543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling during 2 months weight reduction with very-low-energy-diet and 6 months weight maintenance programme including physical activity counselling.
Number of subjects: 36
Study 15543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling during the study period.
Number of subjects: 36
Study 15543160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling and assessments during the study.
Number of subjects: 36
Study 11148432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 16
Study 11148432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9517944 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 12 h)
Number of subjects: 34
Study 9517944 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 34
Study 16892732 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30mg once daily in the morning)
Number of subjects: 20
Study 16892732 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release theophylline (600-800mg per day in b.i.d. dosage)
Number of subjects: 20
Study 2195106 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain enriched amino acid mixture (1 g/kg per day)
Number of subjects: 65
Study 2195106 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric glucose infusion
Number of subjects: 65
Study 7377640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline tablets
Number of subjects: 0
Study 7377640 — intervention group
Group type: COMPARATOR
Intervention: Short acting theophylline tablets
Number of subjects: 0
Study 31689457 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDCS-atDCS
Number of subjects: 11
Study 31689457 — intervention group
Group type: COMPARATOR
Intervention: sham-atDCS
Number of subjects: 11
Study 31416692 — intervention group
Group type: EXPERIMENTAL
Intervention: CTH522 adjuvanted with CAF01 liposomes
Number of subjects: 35
Study 31416692 — intervention group
Group type: EXPERIMENTAL
Intervention: CTH522 adjuvanted with aluminium hydroxide
Number of subjects: 35
Study 31416692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 35
Study 28625451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Number of subjects: 100
Study 28625451 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study 26253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 346
Study 26253568 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma renin
Number of subjects: 346
Study 24476905 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 nerve root transection
Number of subjects: 28
Study 24476905 — intervention group
Group type: COMPARATOR
Intervention: C2 nerve root preservation
Number of subjects: 28
Study 21762554 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 406
Study 21762554 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control)
Number of subjects: 406
Study 21762554 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 406
Study 20621273 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care plus Music Intervention (MI)
Number of subjects: 53
Study 20621273 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 53
Study 17686624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate combined with salmeterol
Number of subjects: 1242
Study 17686624 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 1242
Study 15871754 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) daily for 3 days for intervals of 8, 6, and 4 hours, plus standard therapy
Number of subjects: 25
Study 15871754 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 25
Study 12475399 — intervention group
Group type: EXPERIMENTAL
Intervention: PR + IM
Number of subjects: 76
Study 12475399 — intervention group
Group type: COMPARATOR
Intervention: PR alone
Number of subjects: 76
Study 10487134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (Group I)
Number of subjects: 30
Study 10487134 — intervention group
Group type: COMPARATOR
Intervention: 0.015 mg/kg pancuronium (Group II)
Number of subjects: 30
Study 10487134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rocuronium (Group III)
Number of subjects: 30
Study 8929939 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment (duration not specified, but retention for more than three months is noted)
Number of subjects: 0
Study 8929939 — intervention group
Group type: COMPARATOR
Intervention: Client characteristics (gender, education, age, psychiatric morbidity, drug of choice, attendance at AA/NA meetings, prior treatment histories)
Number of subjects: 0
Study 1973939 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 60
Study 1973939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 60
Study 1973939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 63806 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia during surgery
Number of subjects: 16
Study 63806 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 16
Study 63806 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 16
Study 29253208 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic antismoking poster placed near the tobacco power wall: Yes
Number of subjects: 441
Study 29253208 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic antismoking poster placed near the cash register: Yes
Number of subjects: 441
Study 29253208 — intervention group
Group type: COMPARATOR
Intervention: Graphic antismoking poster placed near the tobacco power wall: No
Number of subjects: 441
Study 29253208 — intervention group
Group type: COMPARATOR
Intervention: Graphic antismoking poster placed near the cash register: No
Number of subjects: 441
Study 29228763 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐0184
Number of subjects: 96
Study 29228763 — intervention group
Group type: COMPARATOR
Intervention: Positive control (no treatment)
Number of subjects: 96
Study 29228763 — intervention group
Group type: EXPERIMENTAL
Intervention: Shield Force Plus
Number of subjects: 96
Study 29228763 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno Select
Number of subjects: 96
Study 29228763 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal
Number of subjects: 96
Study 29228763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhese Universal
Number of subjects: 96
Study 29228763 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond All‐In‐One
Number of subjects: 96
Study 29228763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 96
Study 24594536 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical light music (n=16)
Number of subjects: 49
Study 24594536 — intervention group
Group type: EXPERIMENTAL
Intervention: Popular music (n=17)
Number of subjects: 49
Study 24594536 — intervention group
Group type: COMPARATOR
Intervention: Quiet environment (control group, n=16)
Number of subjects: 49
Study 23265995 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1 g three times daily for 7 days)
Number of subjects: 2061
Study 23265995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2061
Study 21300709 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated office blood pressure
Number of subjects: 555
Study 21300709 — intervention group
Group type: COMPARATOR
Intervention: Manual office blood pressure
Number of subjects: 555
Study 19318384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target blood glucose range of 81 to 108 mg/dL)
Number of subjects: 6104
Study 19318384 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control (target blood glucose of 180 mg/dL or less)
Number of subjects: 6104
Study 19318384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 6104
Study 19318384 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control
Number of subjects: 6104
Study 17089240 — intervention group
Group type: COMPARATOR
Intervention: RVA pacing
Number of subjects: 27
Study 17089240 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOT pacing
Number of subjects: 27
Study 15270803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dose electrical stimulation (50 micro amps) through silver-plated nylon-dacron stocking electrodes for 8 hours a night for 6 weeks
Number of subjects: 30
Study 15270803 — intervention group
Group type: COMPARATOR
Intervention: Control group with identical stockings receiving insignificant current (5 micro amps)
Number of subjects: 30
Study 11772239 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatments targeting specific steps in the disease process, including mycophenolate mofetil and adenosine analogues.
Number of subjects: 0
Study 11772239 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoablative chemotherapy with or without haematopoietic stem cell rescue.
Number of subjects: 0
Study 11772239 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking co-stimulatory molecules (e.g., CD40 ligand, CTLA4-Ig).
Number of subjects: 0
Study 11772239 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking IL-10.
Number of subjects: 0
Study 11772239 — intervention group
Group type: EXPERIMENTAL
Intervention: Treating with DNase or blocking C5 in the complement cascade.
Number of subjects: 0
Study 9204616 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 37
Study 9204616 — intervention group
Group type: COMPARATOR
Intervention: Linton‐Michel tube (LM tube)
Number of subjects: 37
Study 7619743 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 7619743 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0
Study 2912716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 7
Study 2912716 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 1094253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with conjugated Estrogens (Presomen) 1.25 mg/day from day 5 to 24 of the cycle, and synthetic Gestagen 6 mg/day for the last 5, 7, or 10 days of the cycle
Number of subjects: 85
Study 1094253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with conjugated Estrogens (Presomen) and synthetic Gestagen
Number of subjects: 85
Study 31230024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led triage
Number of subjects: 200
Study 31230024 — intervention group
Group type: COMPARATOR
Intervention: GP-led triage
Number of subjects: 200
Study 29245244 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization manipulation treatment once a day and regular training twice a day for a month
Number of subjects: 120
Study 29245244 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy once a day and regular training twice a day for a month
Number of subjects: 120
Study 29245244 — intervention group
Group type: COMPARATOR
Intervention: Regular training twice a day for a month
Number of subjects: 120
Study 26343780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation (3.0 g/d)
Number of subjects: 37
Study 26343780 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (2.8 g/d)
Number of subjects: 37
Study 26343780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 23168298 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (25 μg, 1000 IU)
Number of subjects: 95
Study 23168298 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (25 μg, 1000 IU)
Number of subjects: 95
Study 23168298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 21701326 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaBlade
Number of subjects: 20
Study 21701326 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrosurgery
Number of subjects: 20
Study 19225210 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 25
Study 19225210 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 25
Study 19225210 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 25
Study 19225210 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 25
Study 16924031 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous HT users
Number of subjects: 60
Study 16924031 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular HT users
Number of subjects: 60
Study 16924031 — intervention group
Group type: COMPARATOR
Intervention: Non-HT users
Number of subjects: 60
Study 15650459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific dendritic cell vaccine with GM-CSF, administered subcutaneously once a week for 3 weeks, then once a month for 5 months.
Number of subjects: 20
Study 15650459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific dendritic cell vaccine with GM-CSF
Number of subjects: 20
Study 11302277 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement telephone intervention and self-help workbook
Number of subjects: 102
Study 11302277 — intervention group
Group type: COMPARATOR
Intervention: Self-help workbook only
Number of subjects: 102
Study 11302277 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 102
Study 9431864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy patients
Number of subjects: 12
Study 8513655 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 9
Study 8513655 — intervention group
Group type: EXPERIMENTAL
Intervention: Naringin solution
Number of subjects: 9
Study 8513655 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 17171908 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 11
Study 17171908 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.4 mg/kg)
Number of subjects: 11
Study 17171908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents (Etomidate and Diazepam)
Number of subjects: 11
Study 30273270 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 35
Study 30273270 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study 27808553 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic signs that are representative of their meaning
Number of subjects: 0
Study 27808553 — intervention group
Group type: COMPARATOR
Intervention: Traffic signs that are least representative of their meaning
Number of subjects: 0
Study 25539966 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE plus HIV services
Number of subjects: 11448
Study 25539966 — intervention group
Group type: COMPARATOR
Intervention: HIV services only
Number of subjects: 11448
Study 23725518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F extract (TwHF) 120 mg/day for 3 months, then 60 mg/day for 3 months
Number of subjects: 65
Study 23725518 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg/day for 6 months
Number of subjects: 65
Study 23725518 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF extract
Number of subjects: 65
Study 20943716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection
Number of subjects: 26
Study 20943716 — intervention group
Group type: COMPARATOR
Intervention: Suprascapular nerve block
Number of subjects: 26
Study 18328360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 95
Study 18328360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg
Number of subjects: 95
Study 18328360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 18328360 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 95
Study 17000360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (0.14 mg/kg/min continuous infusion over 2 minutes)
Number of subjects: 47
Study 17000360 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (during DSE after adenosine test)
Number of subjects: 47
Study 17000360 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (in patients with dobutamine-induced wall-motion abnormalities)
Number of subjects: 47
Study 17000360 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography subgroup (12 patients with LAD stenosis)
Number of subjects: 47
Study 14526269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 20 g Dipeptiven (8 g alanine and 13 g glutamine)
Number of subjects: 15
Study 14526269 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline only)
Number of subjects: 15
Study 10911767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol with a mixed meal
Number of subjects: 7
Study 10911767 — intervention group
Group type: COMPARATOR
Intervention: Control (mixed meal without ethanol)
Number of subjects: 7
Study 8776785 — intervention group
Group type: EXPERIMENTAL
Intervention: sabeluzole (SAB)
Number of subjects: 13
Study 1470446 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound
Number of subjects: 41
Study 1470446 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 41
Study 6385648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 89
Study 6385648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 31072395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical bone trajectory (CBT)
Number of subjects: 240
Study 31072395 — intervention group
Group type: COMPARATOR
Intervention: Traditional trajectory (TT)
Number of subjects: 240
Study 29949494 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg once daily)
Number of subjects: 1401
Study 29949494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1401
Study 26176644 — intervention group
Group type: EXPERIMENTAL
Intervention: Test adalimumab (Exemptia)
Number of subjects: 120
Study 26176644 — intervention group
Group type: COMPARATOR
Intervention: Reference adalimumab (Humira)
Number of subjects: 120
Study 26176644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adalimumab preparations
Number of subjects: 120
Study 25245213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=249)
Number of subjects: 521
Study 25245213 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=272)
Number of subjects: 521
Study 21741129 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training
Number of subjects: 0
Study 21741129 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly resistance training
Number of subjects: 0
Study 20390972 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic acculturation
Number of subjects: 2487
Study 17825616 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 5 mg
Number of subjects: 358
Study 17825616 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 358
Study 17825616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 16047530 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression at treatment entry
Number of subjects: 1450